Abstract
Pharmacogenomics is defined as the study of the association between genetics and drug response. This is a rapidly expanding field with the hope that, within a few years, prospective genotyping will lead to patients being prescribed drugs which are both safer and more effective (‘the right drug for the right patient’, or personalized medicine). There are many existing examples in the literature of strong associations between genetic variation and drug response, and some of these even form the basis of accepted clinical tests. The molecular basis for some of these associations is described, and includes examples of variation in genes responsible for absorption and metabolism of the drug, and in target and disease genes. However, there are many issues surrounding the legal, regulatory and ethical framework to these studies that remain unanswered, and a huge amount of education both for the public and haelthcare professionals will be needed bafore the results of this new madicine can be widely accepted.
Full Text
The Full Text of this article is available as a PDF (90.3 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Evans W. E., Relling M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 Oct 15;286(5439):487–491. doi: 10.1126/science.286.5439.487. [DOI] [PubMed] [Google Scholar]
- Hodgson J. Analysts, firms pour cold water on SNP Consortium. Nat Biotechnol. 1999 Jun;17(6):526–526. doi: 10.1038/9823. [DOI] [PubMed] [Google Scholar]
- Nebert D. W. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet. 1997 Feb;60(2):265–271. [PMC free article] [PubMed] [Google Scholar]